Loading...
Epidemiologic associations and results of clinical studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) might help prevent or slow the development of Alzheimer's disease (AD; Journal Watch Nov 23 2001). In this multicenter U.S. trial, 351 AD patients (age, >50; Mini-Mental State Exam score, 13-26) were randomized to receive rofecoxib (25 mg daily), naproxen sodium (220 mg twice daily), or placebo. Regular use of medications such as cholinesterase inhibitors, estrogen, aspirin, and vitamin E was allowed.
At 1 year, intent-to-treat analyses using several standardized cognitive measures showed no significant difference in cognitive decline among the 3 groups. Fatigue, dizziness, and hypertension were more common in the treatment g…